Polidocanol

Summary

Polidocanol (CHEMBL6067961) is an approved small molecule (ATC C05BB02); indicated across 10 conditions including varicose disease and telangiectasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C05BB02
• Indications: 10 conditions
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067961
Name	Polidocanol
Type	Small molecule
Max phase	4
ATC	C05BB02

Also known as: Aethoxysklerol, Asclera, Laureth 9, Lauromacrogol, Lauromacrogol 400, Marlipal 24/90, Nikkol bl-9ex, Polidocanol, Polyoxyl 9 lauryl ether, Varithena, POLIDOCANOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
varicose disease	4	MONDO:0008638	HP:0002619
telangiectasis	4	MONDO:0001576	MONDO:0001576

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
venous insufficiency	3	MONDO:0000945	MONDO:0000945
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
epicondylitis	2	MONDO:0001875	EFO:1001887
hemorrhoid	2	MONDO:0004872	EFO:0009552
melanoma	2	MONDO:0005105	EFO:0000756
disease of the tendon	2	MONDO:0100010	EFO:1001434
neurofibromatosis type 1	1	MONDO:0018975	MONDO:0018975

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
Not specified	10
PHASE2	3
PHASE4	2
PHASE1	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02154789	PHASE4	TERMINATED	An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst
NCT05798936	PHASE4	UNKNOWN	Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst
NCT00348764	PHASE3	COMPLETED	ESGVS: Sclerotherapy With Lauromacrogol
NCT00399451	PHASE1/PHASE2	UNKNOWN	Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)
NCT00442364	PHASE2	COMPLETED	Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
NCT01185951	PHASE2	UNKNOWN	TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies
NCT03754140	PHASE2	WITHDRAWN	Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
NCT06120036	PHASE1	COMPLETED	Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
NCT06132165	PHASE1	COMPLETED	Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
NCT07606391	Not specified	NOT_YET_RECRUITING	Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars
NCT01923064	Not specified	COMPLETED	Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
NCT02468167	Not specified	UNKNOWN	Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO
NCT02468180	Not specified	UNKNOWN	Primary Prophylaxis of Gastric Variceal Bleed
NCT02468206	Not specified	COMPLETED	Secondary Prophylaxis of Gastric Variceal Bleed
NCT03257254	Not specified	COMPLETED	Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
NCT05586919	Not specified	COMPLETED	Treatment of Venous Malformation
NCT05633277	Not specified	UNKNOWN	Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections
NCT05860439	Not specified	COMPLETED	Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
NCT06192472	Not specified	COMPLETED	Investigation Into the Pathophysiology and Treatment of Varicose Veins

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).